Richard Whitley to Cost-Benefit Analysis
This is a "connection" page, showing publications Richard Whitley has written about Cost-Benefit Analysis.
Connection Strength
0.054
-
Antiviral therapy for neonatal herpes simplex virus: a cost-effectiveness analysis. Am J Manag Care. 1997 Oct; 3(10):1551-8.
Score: 0.032
-
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.
Score: 0.022